Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing.
Cohen YC, Zada M, Wang SY, Bornstein C, David E, Moshe A, Li B, Shlomi-Loubaton S, Gatt ME, Gur C, Lavi N, Ganzel C, Luttwak E, Chubar E, Rouvio O, Vaxman I, Pasvolsky O, Ballan M, Tadmor T, Nemets A, Jarchowcky-Dolberg O, Shvetz O, Laiba M, Shpilberg O, Dally N, Avivi I, Weiner A, Amit I. Cohen YC, et al. Among authors: rouvio o. Nat Med. 2021 Mar;27(3):491-503. doi: 10.1038/s41591-021-01232-w. Epub 2021 Feb 22. Nat Med. 2021. PMID: 33619369 Free PMC article.
Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study.
Muchtar E, Gatt ME, Rouvio O, Ganzel C, Chubar E, Suriu C, Tadmor T, Shevetz O, Lavi N, Shochat T, Cohen YC, Avivi I, Raanani P, Magen H. Muchtar E, et al. Among authors: rouvio o. Br J Haematol. 2016 Jan;172(1):89-96. doi: 10.1111/bjh.13799. Epub 2015 Nov 16. Br J Haematol. 2016. PMID: 26567759 Free article.
Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study.
Cohen YC, Magen H, Lavi N, Gatt ME, Chubar E, Horowitz N, Kreiniz N, Tadmor T, Trestman S, Vitkon R, Rouvio O, Shvetz O, Shaulov A, Ziv-Baran T, Avivi I. Cohen YC, et al. Among authors: rouvio o. Ann Hematol. 2020 Jun;99(6):1273-1281. doi: 10.1007/s00277-020-03985-9. Epub 2020 Mar 20. Ann Hematol. 2020. PMID: 32193630
Bortezomib Maintenance Therapy as a Standard of Care Provides Favorable Outcomes in Newly Diagnosed Myeloma Patients: A Multisite Real-Life Study.
Luttwak E, Gatt ME, Lebel E, Lavi N, Tadmor T, Natalia K, Benyamini N, Horowitz N, Geva M, Suriu C, Avivi I, Trestman S, Mittelman M, Rouvio O, Cohen YC. Luttwak E, et al. Among authors: rouvio o. Clin Lymphoma Myeloma Leuk. 2020 Nov;20(11):e850-e857. doi: 10.1016/j.clml.2020.06.002. Epub 2020 Jun 11. Clin Lymphoma Myeloma Leuk. 2020. PMID: 32624446
Primary plasma cell leukemia in the era of novel agents for myeloma - a multicenter retrospective analysis of outcome.
Ganzel C, Rouvio O, Avivi I, Magen H, Jarchowsky O, Herzog K, Cohen Y, Tadmor T, Horwitz NA, Leiba M, Nagler A, Cohen Y, Bulvik S, Polliack A, Rowe JM, Gatt ME; Israeli Multiple Myeloma Study Group. Ganzel C, et al. Among authors: rouvio o. Leuk Res. 2018 May;68:9-14. doi: 10.1016/j.leukres.2018.02.010. Epub 2018 Mar 2. Leuk Res. 2018. PMID: 29501828
Daratumumab for relapsed AL amyloidosis-When cumulative real-world data precedes clinical trials: A multisite study and systematic literature review.
Shragai T, Gatt M, Lavie N, Vaxman I, Tadmor T, Rouvio O, Zektser M, Horowitz N, Magen H, Ballan M, Suru C, Luttwak E, Levi S, Ziv-Baran T, Avivi I, Cohen YC. Shragai T, et al. Among authors: rouvio o. Eur J Haematol. 2021 Feb;106(2):184-195. doi: 10.1111/ejh.13535. Epub 2020 Nov 9. Eur J Haematol. 2021. PMID: 33090552
Clinical features, therapy patterns, outcomes and prognostic factors of solitary plasmacytomas: a report of the Israeli Myeloma Study Group.
Ganzel C, Trestman S, Levi S, Gatt ME, Lavi N, Vaxman I, Rouvio O, Magen H, Lebel E, Horowitz NA, Leiba M, Tadmor T, Herzog Tzarfati K, Surio C, Yeganeh S, Dally N, Avivi I, Cohen YC. Ganzel C, et al. Among authors: rouvio o. Leuk Lymphoma. 2022 Dec;63(14):3448-3455. doi: 10.1080/10428194.2022.2118535. Epub 2022 Sep 8. Leuk Lymphoma. 2022. PMID: 36075048
Higher infection rate after 7- compared with 5-day cycle of azacitidine in patients with higher-risk myelodysplastic syndrome.
Ofran Y, Filanovsky K, Gafter-Gvili A, Vidal L, Aviv A, Gatt ME, Silbershatz I, Herishanu Y, Arad A, Tadmor T, Dally N, Nemets A, Rouvio O, Ronson A, Herzog-Tzarfati K, Akria L, Braester A, Hellmann I, Yeganeh S, Nagler A, Leiba R, Mittelman M, Merkel D. Ofran Y, et al. Among authors: rouvio o. Clin Lymphoma Myeloma Leuk. 2015 Jun;15(6):e95-9. doi: 10.1016/j.clml.2015.02.030. Epub 2015 Mar 5. Clin Lymphoma Myeloma Leuk. 2015. PMID: 25819366
Primary peg-filgrastim prophylaxis versus filgrastim given "on demand" for neutropenia during therapy with cladribine for hairy cell leukemia.
Tadmor T, Levy I, Herishanu Y, Goldschmidt N, Bairey O, Yuklea M, Shvidel L, Fineman R, Aviv A, Ruchlemer R, Braester A, Dally N, Rouvio O, Shaulov A, Greenbaum U, Inbar M, Polliack A. Tadmor T, et al. Among authors: rouvio o. Leuk Res. 2019 Jul;82:24-28. doi: 10.1016/j.leukres.2019.05.006. Epub 2019 May 19. Leuk Res. 2019. PMID: 31152919
Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: a retrospective multicenter study.
Merkel D, Filanovsky K, Gafter-Gvili A, Vidal L, Aviv A, Gatt ME, Silbershatz I, Herishanu Y, Arad A, Tadmor T, Dally N, Nemets A, Rouvio O, Ronson A, Herzog-Tzarfati K, Akria L, Braester A, Hellmann I, Yeganeh S, Nagler A, Leiba R, Mittelman M, Ofran Y. Merkel D, et al. Among authors: rouvio o. Am J Hematol. 2013 Feb;88(2):130-4. doi: 10.1002/ajh.23368. Am J Hematol. 2013. PMID: 23345248 Free article.
18 results